Thursday, November 27, 2014 Last update: 11:33 AM
FreshNews.com - Covering Large & Obscure Tech Companies Since 1996

NPS Pharma to Report Second Quarter 2014 Financial Results

Companies mentioned in this article: NPS Pharmaceuticals, Inc.

BEDMINSTER, N.J. -- (BUSINESS WIRE) -- NPS Pharmaceuticals, Inc. (Nasdaq:NPSP) announced today that it will report its second 2014 financial results on Wednesday, August 6, 2014 at approximately 4:30 p.m. ET. The press release will be followed by a conference call and webcast at 5:00 p.m. ET.

To participate in the conference call, dial (800) 510-9691 and use passcode 89848006. International callers may dial +1 (617) 614-3453, using the same passcode. In addition, a live audio of the conference call will be available over the Internet. Interested parties can access the event through the investors’ calendar of events page on the NPS website at http://www.npsp.com/calendar.

If you are unable to participate in the live call, a replay will be available at (888) 286-8010, with passcode 42267576 until midnight ET, August 20, 2014. International callers may access the replay by dialing +1 (617) 801-6888, using the same passcode. The webcast will also be available through the NPS website for the same period.

About NPS Pharma

NPS Pharma is a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases. The company’s current therapeutic areas of focus are rare gastrointestinal disease and endocrine disorders. These include Short Bowel Syndrome, a potentially fatal gastrointestinal disorder in which patients may have to rely on parenteral nutrition for their survival; Hypoparathyroidism, a complex endocrine disorder in which the parathyroid glands are either absent or damaged, and the body produces insufficient or no parathyroid hormone; and Autosomal Dominant Hypocalcemia, an ultra-rare, genetic disorder of calcium homeostasis caused by mutations of the calcium-sensing receptor gene. NPS Pharma continues to seek in-licensing opportunities to develop new therapies for a broad range of rare diseases, and complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, and Kyowa Hakko Kirin. NPS Pharma has operations in the U.S., Canada, Europe, Latin America and Japan. Learn more at: www.npsp.com.

“NPS Pharma” and “NPS Pharmaceuticals” are the company's trademarks.


Copyright © Business Wire 2014
Contact:

NPS Pharmaceuticals, Inc.
Gail Brophy, +1 908-450-5335
gbrophy@npsp.com